公开(公告)号：US20210105980A1

公开(公告)日：2021-04-15

申请号：US17050199

申请日：2019-04-25

Applicant: Hoffmann-La Roche Inc. ,  HOFFMANN-LA ROCHE INC.

Inventor： Przemek IDZIASZEK ,  Antoni OPOLSKI ,  Jacek ZIEMSKI ,  Bartosz BINIAS

IPC: A01K29/00 ,  A01K11/00

Abstract: A method of tracking an animal (4) in a population of animals (4) comprises: applying a visual identifier (41) to the animal (4); associating reference identifier data of the visual identifier (41) to animal data of the animal (4); capturing a digital image of the visual identifier (41) applied to the animal (4); recognizing the visual identifier (41) by digitally processing the captured digital image; and identifying the animal (4) upon recognition of the visual identifier (41).

公开(公告)号：US20200071411A1

公开(公告)日：2020-03-05

申请号：US16684258

申请日：2019-11-14

Applicant: Hoffmann-La Roche Inc. ,  Hoffmann-La Roche Inc.

Inventor： Maria AMANN ,  Peter BRUENKER ,  Christina CLAUS ,  Claudia FERRARA KOLLER ,  Sandra GRAU-RICHARDS ,  Ralf HOSSE ,  Christian KLEIN ,  Viktor LEVITSKI ,  Pablo UMANA

IPC: C07K16/28 ,  C07K16/30 ,  C07K16/40

Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) at least one moiety capable of specific binding to a costimulatory TNF receptor family member, and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

公开(公告)号：US20250059185A1

公开(公告)日：2025-02-20

申请号：US18720022

申请日：2022-12-14

Applicant: Hoffmann-La Roche Inc.

Inventor： Joerg BENZ ,  Maude GIROUD ,  Uwe GRETHER ,  Bernd KUHN ,  Fionn Susannah O'HARA ,  Matthias Beat WITTWER

IPC: C07D471/04 ,  A61K9/20 ,  A61K9/48 ,  A61K31/437 ,  A61K31/444 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/675 ,  C07D487/04 ,  C07D519/00 ,  C07F9/6561

Abstract: The invention provides new MAGL inhibitors having the general formula (II)AB(II) wherein the variables are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

公开(公告)号：US20250059155A1

公开(公告)日：2025-02-20

申请号：US18776585

申请日：2024-07-18

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Rene LEBL ,  Ngiap Kie LIM ,  Roland Christoph MEIER ,  Ugo Jonathan ORCEL ,  Joerg SEDELMEIER ,  Jeff SHEN ,  Lauren Elizabeth SIROIS ,  Jacob C. TIMMERMAN ,  Etienne TRACHSEL ,  Nicholas Andrew WHITE ,  Jie XU ,  Haiming ZHANG ,  Stephan BACHMANN ,  Thomas Michael BASS ,  Raphael BIGLER ,  Johannes Adrian BURKHARD ,  Kyle Bradley Pascual CLAGG ,  Francis GOSSELIN ,  Chong HAN ,  Dainis KALDRE ,  Sean M. KELLY ,  Sebastian HEROLD ,  Christian LEITNER

IPC: C07D401/04 ,  B01J23/44 ,  B01J23/755

Abstract: Provided herein are methods to synthesize compounds useful in the treatment of cancer where such compounds comprise a quinazolinyl core moiety and at least one stereoisomeric or atropisomeric moiety.

公开(公告)号：US12221420B2

公开(公告)日：2025-02-11

申请号：US17571182

申请日：2022-01-07

Applicant: Hoffmann-La Roche Inc.

Inventor： Paul Spurr ,  Rene Trussardi

IPC: C07D231/14

Abstract: The invention provides a process for manufacturing 5-ethyl-4-methyl-N-[4-[(2S) morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide (Formula I), or a pharmaceutically acceptable salt thereof, on an industrial scale, comprising a one-pot process for manufacturing 5-ethyl-4-methyl-1H-pyrazole-3-carboxylic acid (1).

公开(公告)号：US20250034576A1

公开(公告)日：2025-01-30

申请号：US18743170

申请日：2024-06-14

Applicant: Hoffmann-La Roche Inc.

Inventor： Philipp Friedrich BERNINGER ,  Konrad BLEICHER ,  Erik FUNDER ,  Helle JACOBSEN ,  Dennis Jul HANSEN ,  Michael KELLER ,  Inna Appeldorff LARSEN ,  Meiling LI ,  Disa Elisabet TEHLER ,  Lotte WINTHER ,  Jesper WORM ,  Lena WYSS ,  Tiago Francisco SANTOS FERREIRA

IPC: C12N15/113

Abstract: The present invention relates to double stranded oligonucleotides that are complementary to JAK1, leading to modulation of the expression of JAK1. Modulation of JAK1 expression is beneficial for a range of medical disorders including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. Also included are compositions comprising the double stranded oligonucleotide and methods of treatment using the double stranded oligonucleotide.

公开(公告)号：US20250034269A1

公开(公告)日：2025-01-30

申请号：US18747055

申请日：2024-06-18

Applicant: Hoffmann-La Roche Inc.

Inventor： Roberta Bianchi ,  Felix Bormann ,  Michelle Victoria Brydon ,  Stefan Dengl ,  Harald Duerr ,  Guy Georges ,  Lydia Jasmin Hanisch ,  Monika Heidrich ,  Ralf Hosse ,  Leo Frederik Kunz ,  Stephane Leclair ,  Desirée Leisibach ,  Fanny Mende ,  Olaf Mundigl ,  Miroslav Nikolov ,  Pablo Umaña ,  Cornelia Wagner

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/40

Abstract: The invention relates to novel antibodies that bind to lymphotoxin beta receptor (LTBR) and to bispecific antigen binding molecules comprising these novel LTBR antibodies and an antigen binding domain that binds a tumor associated antigen, in particular to Fibroblast Activation Protein (FAP), to methods of producing these molecules and to methods of using the same.

公开(公告)号：US12202870B2

公开(公告)日：2025-01-21

申请号：US17455617

申请日：2021-11-18

Applicant: Hoffmann-La Roche Inc.

Inventor： Maria Amann ,  Peter Bruenker ,  Christina Claus ,  Claudia Ferrara Koller ,  Sandra Grau-Richards ,  Christian Klein ,  Viktor Levitski ,  Ekkehard Moessner ,  Pablo Umana

IPC: C07K14/525 ,  A61K38/00 ,  A61K39/395 ,  C07K14/705 ,  C07K16/28 ,  C07K16/30 ,  C07K16/40

Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

公开(公告)号：US20250017937A1

公开(公告)日：2025-01-16

申请号：US18779430

申请日：2024-07-22

Applicant: Hoffmann-La Roche Inc.

Inventor： Theresa M. BALLARD ,  Silvia Gatti MCARTHUR ,  Michael SAXE ,  Juergen WICHMANN ,  Thomas WOLTERING

IPC: A61K31/519 ,  A61K31/444

Abstract: This invention relates to a new medical use for certain chemical compounds and pharmaceutical compositions containing them. The invention relates to compounds which are mGlu2/3 negative allosteric modulators for use in the treatment of intellectual disabilities. In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of intellectual disabilities comprising a compound according to the invention and a pharmaceutically acceptable carrier.

公开(公告)号：US12186392B2

公开(公告)日：2025-01-07

申请号：US16679483

申请日：2019-11-11

Applicant: Ono Pharmaceutical Co., Ltd. ,  HOFFMANN-LA ROCHE INC.

Inventor： Christian Klein ,  Toshio Yoshizawa ,  Tomoko Yasuhiro

IPC: A61K39/395 ,  A61K31/522 ,  A61K39/40 ,  A61K45/06 ,  C07K16/28 ,  A61K39/00 ,  C07K16/00

Abstract: The present invention is directed to the combination therapy of an anti-CD20 antibody with a BTK inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with a type I anti-CD20 antibody or an afucosylated humanized B-Ly1 antibody and a BTK inhibitor.